Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection

American Journal of Infection Control

Volumn 46, Issue 3, 2018, Pages 270-275

  Crew, Page E ^a,b   Rhodes, Nathaniel J ^a,b   O'Donnell, J Nicholas ^a,b   Miglis, Cristina ^a,b   Gilbert, Elise M ^b,c   Zembower, Teresa R ^b,d   Qi, Chao ^d   Silkaitis, Christina ^b   Sutton, Sarah H ^b,d   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c CHICAGO STATE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antibiotic use; Antimicrobial stewardship; Healthcare associated infections; Statistical model

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG USE; GRAFT RECIPIENT; HEALTH CARE FACILITY ONSET CLOSTRIDIUM DIFFICILE INFECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; ANTIMICROBIAL STEWARDSHIP; CLOSTRIDIUM INFECTION; CROSS INFECTION; DRUG UTILIZATION; HOSPITAL; MICROBIOLOGY; MORALITY; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL STEWARDSHIP; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG UTILIZATION; HOSPITALS; HUMANS; RETROSPECTIVE MORAL JUDGMENT;

EID: 85034989462     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2017.09.015     Document Type: Article

References (27)

1. Lessa, F.C., Winston, L.G., McDonald, L.C., Emerging Infections Program CdST. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 2369–2370.
2. Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
3. Hensgens, M.P., Goorhuis, A., Dekkers, O.M., Kuijper, E.J., Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67 (2012), 742–748.
4. Pepin, J., Saheb, N., Coulombe, M.A., Alary, M.E., Corriveau, M.P., Authier, S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005), 1254–1260.
5. Centers for Disease Control and Prevention (CDC), Antibiotic Resistance Threats in the United States. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/, 2013. (Accessed 13 June 2016)
6. Centers for Disease Control and Prevention (CDC), Vital Signs Technical Appendix: Estimating the Potential Reductions in Clostridium difficile Infection (CDI) among Patients when Antibiotic Use is Improved. Available from: http://www.cdc.gov/getsmart/healthcare/evidence/cdiff.html, 2015. (Accessed 13 June 2016)
7. Slimings, C., Riley, T.V., Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 881–891.
8. Owens, R.C. Jr, Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Suppl 1 (2008), S19–S31.
9. Centers for Disease Control and Prevention (CDC), Making Health Care Safer: Antibiotic Rx in Hospitals: Proceed with Caution. Available from: http://www.cdc.gov/vitalsigns/antibiotic-prescribing-practices, 2014. (Accessed 13 June 2016)
10. Hecker, M.T., Aron, D.C., Patel, N.P., Lehmann, M.K., Donskey, C.J., Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 163 (2003), 972–978.
11. Centers for Disease Control and Prevention (CDC), Get Smart for Healthcare. Available from: http://www.cdc.gov/getsmart/healthcare/, 2016. (Accessed 24 August 2016)
12. Dancer, S.J., Kirkpatrick, P., Corcoran, D.S., Christison, F., Farmer, D., Robertson, C., Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum beta-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 41 (2013), 137–142.
13. Valiquette, L., Cossette, B., Garant, M.P., Diab, H., Pepin, J., Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 45:Suppl 2 (2007), S112–S121.
14. Cruz-Rodriguez, N.C., Hernandez-Garcia, R., Salinas-Caballero, A.G., Perez-Rodriguez, E., Garza-Gonzalez, E., Camacho-Ortiz, A., The effect of pharmacy restriction of clindamycin on Clostridium difficile infection rates in an orthopedics ward. Am J Infect Control 42 (2014), e71–e73.
15. Fridkin, S., Baggs, J., Fagan, R., Magill, S., Pollack, L.A., Malpiedi, P., et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 63 (2014), 194–200.
16. Brown, K., Valenta, K., Fisman, D., Simor, A., Daneman, N., Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med 175 (2015), 626–633.
17. Shaughnessy, M.K., Micielli, R.L., DePestel, D.D., Arndt, J., Strachan, C.L., Welch, K.B., et al. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 32 (2011), 201–206.
18. Riggs, M.M., Sethi, A.K., Zabarsky, T.F., Eckstein, E.C., Jump, R.L., Donskey, C.J., Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45 (2007), 992–998.
19. Sethi, A.K., Al-Nassir, W.N., Nerandzic, M.M., Bobulsky, G.S., Donskey, C.J., Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 31 (2010), 21–27.
20. Centers for Disease Control and Prevention (CDC), Multidrug-Resistant Organism & Clostridium difficile Infection (MDRO/CDI) Module. Available from: http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf, 2016. (Accessed 13 June 2016)
21. National Healthcare Safety Network (NHSN), Antimicrobial Use and Resistance (AUR) Module. Available from: http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf, 2016. (Accessed 13 June 2016)
22. Rhodes, N.J., Wagner, J.L., Gilbert, E.M., Crew, P.E., Davis, S.L., Scheetz, M.H., Days of therapy and antimicrobial days: similarities and differences between consumption metrics. Infect Control Hosp Epidemiol 37 (2016), 971–973.
23. Scheetz, M.H., Crew, P.E., Miglis, C., Gilbert, E.M., Sutton, S.H., O'Donnell, J.N., et al. Investigating the extremes of antibiotic use with an epidemiologic framework. Antimicrob Agents Chemother 60 (2016), 3265–3269.
24. Sun, L., Klein, E.Y., Laxminarayan, R., Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 55 (2012), 687–694.
25. Büchler, A.C., Rampini, S.K., Stelling, S., Ledergerber, B., Peter, S., Schweiger, A., et al. Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infect Dis, 14, 2014, 607, 10.1186/s12879-014-0607-z.
26. Aldeyab, M.A., Harbarth, S., Vernaz, N., Kearney, M.P., Scott, M.G., Funston, C., et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 53 (2009), 2082–2088.
27. Bender, R., Lange, S., Adjusting for multiple testing–when and how?. J Clin Epidemiol 54 (2001), 343–349.